Complete

Using AI to predict drug resistance mutations in breast cancer

Cancer types:

Breast cancer

Project period:

Research institute:

Institut Curie

Award amount:

£115,133

Location:

France

Researcher Dr Anne Vincent-Salomon

Dr Anne Vincent-Salomon and her team, with the inspiring help of Professors Bidard and Walter at Institut Curie, are developing an artificial intelligence tool that could be used to predict which patients are going to develop genetic mutations that make them resistant to treatment. 

Hope for the future

 Breast cancer is the most common cancer in women worldwide, with an estimated 2.3 million women diagnosed 2020. Hormone therapies are a common treatment for breast cancer and can be very effective for some patients, however some people can develop resistance to treatment. 

Dr Anne Vincent-Salomon and her team are developing a new tool that uses artificial intelligence to predict resistance mutations before they even occur. They are training their tool using images of breast tumours to identity characteristics of the tumours that can predict resistance. This tool could help improve the clinical decision making for breast cancer patients by helping doctors to identify people who are likely to develop resistance to a treatment. These patients could then be offered tailored treatment options that would be more effective for their individual cancer. 

Meet the scientist

Beyond being a breast pathologist, Dr Anne Vincent-Salomon is a mom of 3 and a passionate hiker. She loves being outdoors, hiking in the South of France or in Corsica, and in the streets of Paris. 

The science

Around 70% of breast cancers are diagnosed as ER-positive, which means that the cancer cells produce too much of a protein called the oestrogen receptor and become dependent on the hormone oestrogen to grow. Therapies that target this dependence on oestrogen, such as aromatase inhibitors, are a common treatment for this type of breast cancer but some people can develop resistant to treatment over time. Research has shown that one way this resistance develops is due to mutations to a gene called ESR1, which seem to emerge in response to treatment with aromatase inhibitors. 

Dr Anne Vincent Salomon and her team are studying whether there are characteristics of breast tumours that are visible prior to treatment, which could be used to predict who will develop mutations to the ESR1 gene, and even predict who will develop resistance to treatment. The team will use images captured from thin slices of tumours donated from breast cancer patients to train a deep learning artificial intelligence tool. They hope that this tool will identify predictive characteristics of breast tumours that will be able to improve how patients are treated in the future. 

I have a personal family history of breast cancer and cannot get used to the huge number of women affected by this disease. All my efforts are dedicated to a better understanding of this disease. 

Dr Anne Vincent-Salomon

Related projects

Active Spain

Breast cancer

How does a faulty BRCA2 gene cause breast cancer to develop?

The team hope that by understanding how different mutations contribute to breast cancer, they can reveal new ways to prevent, diagnose and treat it.  

Researcher: Dr Aura Carreira

Uncovering how a faulty BRCA2 gene causes breast cancer to develop

Active Sweden

Multiple cancers

How does ‘tissue stiffening’ affect cancer development?

This project hopes to discover more about the biology of how solid tumours develop to find new ways to prevent, diagnose or treat these cancers.

Researcher: Professor Staffan Stromblad

Understanding how 'tissue stiffening' affects cancer development

Active Italy

General cancer research

Could nanoparticle 'smart bombs' target hard-to-treat tumours?

Once cancer has spread, or metastasised, it often becomes incurable. This project is investigating new ways to deliver drugs specifically to metastatic tumours.

Researcher: Professor Roberta Tasso

Developing natural nanoparticle “smart bombs” to target hard-to-treat tumours
Share this page